Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 8/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713887 | 0.79 | ILK (0.65) | ILKCCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL714081 | 0.78 | MEN1 (0.56) | ILKKDM4EALDH1A1LMNACYP2C9 | |
| SCHEMBL687095 | 0.73 | ILK (0.54) | ILK | |
| SCHEMBL687104 | 0.72 | ILK (0.64) | ILK | |
| SCHEMBL686526 | 0.72 | ILK (0.60) | ILK | |
| SCHEMBL15113243 | 0.72 | MEN1 (0.67) | ALDH1A1LMNATDP1 | |
| SCHEMBL686380 | 0.71 | ILK (0.49) | ILK | |
| SCHEMBL687525 | 0.68 | ILK (0.55) | ILK | |
| SCHEMBL713988 | 0.68 | ALDH1A1 (0.64) | KDM4EALDH1A1LMNACYP2C9EDNRA | |
| Hydrochloric Acid SCHEMBL8933679 | 0.68 | EGFR (0.60) | ILKCDK2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | claimed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | claimed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | claimed |
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8754233-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8410272-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DERMIRA (CANADA), INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Valocor Therapeutics, Inc. (CA) | 2011-07-21 | — | — | US | disclosed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | ILK 2153/4885CCNE1 1384/4885CDK2 185/4885 |
| US-20110178126-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | REN, PGF, PKD1 | ILK 1603/4885CCNE1 37/4885CDK2 9/4885 |
| US-20130237572-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | ILK 4705/4885CCNE1 1960/4885CDK2 970/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | ILK 4705/4885CCNE1 1960/4885CDK2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.